Hyderabad-based pharmaceutical company Biological E Limited has entered into an agreement with US-based biotechnology company VaxInnate Corporation to license its recombinant H1N1 pandemic swine flu vaccine.
Under this, Biological E would produce vaccine for India and other South Asian countries, including Bangladesh, Bhutan, the Maldives, Nepal, Pakistan and Sri Lanka.
The vaccine is projected to enter clinical development in India in early 2010.
Assuming positive clinical results, the vaccine could become available for emergency use in India by mid 2010, a company release said. Biological E has a capacity to produce over 300 million vaccine doses every month.
